Best strategies for global HCV eradication

被引:79
作者
Hagan, Liesl M.
Schinazi, Raymond F. [1 ,2 ]
机构
[1] Emory Univ, Sch Med, Ctr AIDS Res, Decatur, GA 30033 USA
[2] Vet Affairs Med Ctr, Decatur, GA 30033 USA
关键词
cure; direct-acting antiviral; linkage to care; prevention; testing; universal screening; HEPATITIS-C VIRUS; INJECTION-DRUG USERS; TO-CHILD TRANSMISSION; COST-EFFECTIVENESS; SEXUAL TRANSMISSION; RISK-FACTORS; PEGINTERFERON ALPHA-2B; ANTIVIRAL THERAPY; DECISION-MAKING; PLUS RIBAVIRIN;
D O I
10.1111/liv.12063
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Worldwide eradication of hepatitis C virus (HCV) is possible through a combination of prevention education, universal clinical and targeted community screening, effective linkage to care and treatment with promising new direct-acting antiviral drug regimens. Universal screening should be offered in all healthcare visits, and parallel community screening efforts should prioritize high-prevalence, high-transmission populations including injection drug users, prison inmates and those with HIV/HCV co-infection. Increasing awareness of HCV infection through screening, improving treatment uptake and cure rates by providing linkage to care and more effective treatment, and ultimately combining education efforts with vaccination campaigns to prevent transmission and reinfection can slow and eventually stop the silent epidemic.
引用
收藏
页码:68 / 79
页数:12
相关论文
共 122 条
  • [1] Hepatitis C: The End of the Beginning and Possibly the Beginning of the End
    Alter, Harvey J.
    Liang, T. Jake
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 156 (04) : 317 - U111
  • [2] Epidemiology of hepatitis C virus infection
    Alter, Miriam J.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (17) : 2436 - 2441
  • [3] [Anonymous], 2011, COMB SIL EP VIR HEP
  • [4] [Anonymous], 2002, NIH CONSENS STATE SC, V19, P1
  • [5] [Anonymous], HEP LIV CANC NAT STR
  • [6] Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5
    Antaki, N.
    Hermes, A.
    Hadad, M.
    Ftayeh, M.
    Antaki, F.
    Abdo, N.
    Kebbewar, K.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2008, 15 (05) : 383 - 386
  • [7] The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
    Armstrong, Gregory L.
    Wasley, Annemarie
    Simard, Edgar P.
    McQuillan, Geraldine M.
    Kuhnert, Wendi L.
    Alter, Miriam J.
    [J]. ANNALS OF INTERNAL MEDICINE, 2006, 144 (10) : 705 - 714
  • [8] IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Asselah, Tarik
    De Muynck, Simon
    Broet, Philippe
    Masliah-Planchon, Julien
    Blanluet, Maud
    Bieche, Ivan
    Lapalus, Martine
    Martinot-Peignoux, Michelle
    Lada, Olivier
    Estrabaud, Emilie
    Zhang, Qian
    El Ray, Ahmed
    Vidaud, Dominique
    Ripault, Marie-Pierre
    Boyer, Nathalie
    Bedossa, Pierre
    Valla, Dominique
    Vidaud, Michel
    Marcellin, Patrick
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (03) : 527 - 532
  • [9] Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States
    Averhoff, Francisco M.
    Glass, Nancy
    Holtzman, Deborah
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 55 : S10 - S15
  • [10] Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection
    Bica, I
    McGovern, B
    Dhar, R
    Stone, D
    McGowan, K
    Scheib, R
    Snydman, DR
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) : 492 - 497